FDA approved levacetylleucine (Aqneursa) for ataxia in ataxia-telangiectasia, the first therapy for the disease, in patients 15 kg or heavier.
|Articles|November 4, 2005
Will a lab test take us a step closer to "personalized medicine"? Approval of a genetic assay for drug utilization suggests so
The US Food and Drug Administration has approved a genetics-based test that detects how certain drugs are utilized in the body. The Invader UGT1A1 Molecular Assay detects variations in the gene UGT1A1, which produces an enzyme that is active in the metabolism of certain drugs, including irinotecan (Camptosar), used to treat colorectal cancer.
Advertisement
Advertisement
Related to this article
Tallie Z. Baram, MD, talks about how adding a measure of childhood unpredictability to ACEs screening may help pediatricians identify children at risk for mental health problems.
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
The FDA granted priority review to efzimfotase alfa for HPP in patients aged 2 years and older; a decision is expected in the first half of 2027.
Adolescent VALIANT subgroup data show pegcetacoplan cut proteinuria 75% vs placebo, supporting its expanded pediatric kidney indication.
The FDA approved Fayuvi (rebisufligene etisparvovec-hopf), a one-time AAV9 gene therapy, as the first treatment for pediatric MPS IIIA (Sanfilippo syndrome type A).
Aquestive resubmitted its NDA for dibutepinephrine sublingual film Anaphylm, citing new human factors and PK data addressing the FDA's CRL.
Melissa Wallach, MD, FAAP, discusses what pediatricians should know about updated screening, supplementation, and treatment recommendations for iron deficiency.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Updated AAP guidance changes iron deficiency screening and treatment in children
2
Tezepelumab meets co-primary and secondary endpoints in phase 3 eosinophilic esophagitis trial
3
FDA approves levacetylleucine as first treatment for ataxia in ataxia-telangiectasia
4
Childhood unpredictability may identify mental health risk missed by ACEs screening
5